Track topics on Twitter Track topics that are important to you
An initial public offering was filed with the SEC by Basking Ridge, N.J.-based electroCore in hopes of raising up to $75 mill -More-
An initial public offering of 4.3 million shares has been priced by electroCore between $14 and $16 each in hopes of raising -More-
The FDA granted electroCore 510(k) clearance for its gammaCore device for use in acute treatment of migraine pain in adults. -More-
Noninvasive vagus nerve stimulation (nVNS) device company electroCore LLC (focused on neurology and rheumatology) filed for its initial public offering.
Bioelectronic medicines company electroCore LLC (neuromodulation technologies) completed a $70.9mm Series B round led by returning investor Core Ventures II, which was joined by another Series A parti...
To evaluate the efficacy, safety, and tolerability of noninvasive vagus nerve stimulation (nVNS; gammaCore; electroCore, LLC, Basking Ridge, NJ) for the acute treatment of migraine in a multicenter, d...
The tasks of the project are to map the potency and kinetics of the neurologic, autonomic peripheral, inflammatory, and behavioral responses to vagal nerve stimulation (VNS) vs. sham treat...
electroCore LLC, the New Jersey based bioelectric pharma company, is focused on developing non-invasive vagus nerve stimulation therapies (the gammaCore device) for the treatment ...
electroCore LLC, the New Jersey based bioelectric pharma company, is focused on developing non-invasive vagus nerve stimulation therapies for the treatment of multiple conditions ...
We have published hundreds of electroCore news stories on BioPortfolio along with dozens of electroCore Clinical Trials and PubMed Articles about electroCore for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of electroCore Companies in our database. You can also find out about relevant electroCore Drugs and Medications on this site too.